dc.contributor.author | Strydom, A | en_US |
dc.contributor.author | Heslegrave, A | en_US |
dc.contributor.author | Startin, CM | en_US |
dc.contributor.author | Mok, KY | en_US |
dc.contributor.author | Hardy, J | en_US |
dc.contributor.author | Groet, J | en_US |
dc.contributor.author | Nizetic, D | en_US |
dc.contributor.author | Zetterberg, H | en_US |
dc.contributor.author | LonDownS Consortium | en_US |
dc.date.accessioned | 2018-09-26T15:12:57Z | |
dc.date.available | 2018-03-14 | en_US |
dc.date.issued | 2018-04-10 | en_US |
dc.date.submitted | 2018-04-12T09:50:58.808Z | |
dc.identifier.other | 10.1186/s13195-018-0367-x | |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/45363 | |
dc.description | This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. | en_US |
dc.description.abstract | BACKGROUND: Down syndrome (DS) may be considered a genetic form of Alzheimer's disease (AD) due to universal development of AD neuropathology, but diagnosis and treatment trials are hampered by a lack of reliable blood biomarkers. A potential biomarker is neurofilament light (NF-L), due to its association with axonal damage in neurodegenerative conditions. METHODS: We measured blood NF-L concentrations in 100 adults with DS using Simoa NF-light® assays, and we examined relationships with age as well as cross-sectional and longitudinal dementia diagnosis. RESULTS: NF-L concentrations increased with age (Spearman's rho = 0.789, p < 0.001), with a steep increase after age 40, and they were predictive of dementia status (p = 0.022 adjusting for age, sex, and APOE4), but they showed no relationship with long-standing epilepsy or premorbid ability. Baseline NF-L concentrations were associated with longitudinal dementia status. CONCLUSIONS: NF-L is a biomarker for neurodegeneration in DS with potential for use in future clinical trials to prevent or delay dementia. | en_US |
dc.description.sponsorship | This work was funded by a Wellcome Trust Strategic Award (grant number 098330/Z/12/Z) conferred upon The London Down Syndrome (LonDownS) Consortium (Chief Investigator, Andre Strydom). | en_US |
dc.format.extent | 39 - ? | en_US |
dc.language | eng | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Alzheimers Res Ther | en_US |
dc.subject | Alzheimer’s disease | en_US |
dc.subject | Biomarker | en_US |
dc.subject | Dementia | en_US |
dc.subject | Down syndrome | en_US |
dc.subject | Neurofilament light | en_US |
dc.title | Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. | en_US |
dc.type | Article | |
dc.rights.holder | Creative Commons Attribution License | |
dc.rights.holder | The Author(s) 2018 | |
dc.identifier.doi | 10.1186/s13195-018-0367-x | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/29631614 | en_US |
pubs.issue | 1 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published online | en_US |
pubs.volume | 10 | en_US |
dcterms.dateAccepted | 2018-03-14 | en_US |